Mylan Settles Drug Lawsuit with Novartis

Mylan has settled a patent litigation lawsuit with Novartis Pharmaceuticals related to Vivelle-Dot.

US-based pharmaceutical company Mylan Inc.has settled a patent litigation lawsuit with Novartis Pharmaceuticals Corporation related to Vivelle-Dot? (Estradiol Transdermal System USP, Twice-Weekly, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day and 0.075 mg/day and 0.1 mg/day).

According to the agreement, pending litigation will be dismissed, and Mylan will receive a patent license to begin selling generic versions of the product on Dec. 16, 2013, or earlier under certain circumstances.

Additional details of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Mylan was the first company